Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
    • State Disclosures
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Cocaine Intoxication
      • Migraine
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Mpox (Monkey Pox)
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-801
      • TNX-1800
      • TNX-4200 CD45
    • Rare Disease
      • TNX-2900
    • Expanded Access Policy
  • Medicines
  • Clinical Trials
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • Investor Presentations
    • Scientific Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
      • Investor Presentations
      • Scientific Presentations
      • Program Specific Presentations
      • Fact Sheet
      • Conference Materials
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Tonix in the News
    • Tonix Sponsored News
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
    • Form 8937
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Tonix in the News
  • Tonix Sponsored News
  • IR Events
  • Email Alerts
  • Op-Eds
Aug 4, 2020 9:00am EDT

Tonix Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement

Aug 4, 2020 7:00am EDT

Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference

Jul 30, 2020 7:00am EDT

Tonix Pharmaceuticals to Participate in SNN Network Virtual Investor Conference

Jul 27, 2020 7:00am EDT

Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference

Jul 21, 2020 4:45pm EDT

Tonix Pharmaceuticals Holding Corp. Announces Rescheduling of Special Meeting of Stockholders

Jul 16, 2020 9:00am EDT

Tonix Pharmaceuticals Announces Research Collaboration to Develop Precision Medicine Techniques for COVID-19 Vaccines and Therapeutics

Jul 15, 2020 5:00pm EDT

Tonix Pharmaceuticals Holding Corp. Closes $10.5 Million Common Stock Registered Direct Offering

Jul 13, 2020 1:11pm EDT

Tonix Pharmaceuticals Holding Corp. Prices $10,500,000 Common Stock Offering

Jul 13, 2020 7:00am EDT

Tonix Pharmaceuticals Enters into Research and Exclusive License Option Agreement with Kansas State University to Develop Vaccine Against COVID-19

Jul 10, 2020 7:00am EDT

Tonix Pharmaceuticals Completes Enrollment in Phase 3 RELIEF Trial of TNX-102 SL for Management of Fibromyalgia

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2025 Tonix Pharmaceuticals Holding Corp.